Bexxar Related Published Studies
Well-designed clinical trials related to Bexxar (Tositumomab / Iodine I 131 Tositumomab)
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. [2005.10.20]
Well-designed clinical trials possibly related to Bexxar (Tositumomab / Iodine I 131 Tositumomab)
The radioisotope contributes significantly to the activity of radioimmunotherapy. [2004.12.01]
Other research related to Bexxar (Tositumomab / Iodine I 131 Tositumomab)
Six of 12 relapsed or refractory indolent lymphoma patients treated 10 years ago with 131I-tositumomab remain in complete remission. [2011.06]
Tositumomab and iodine I 131 tositumomab (Bexaar). [2011.04]
Dosimetry in patients with B-cell lymphoma treated with [(90)Y]ibritumomab tiuxetan or [(131)I]tositumomab. [2011.04]
Predicting hematologic toxicity in patients undergoing radioimmunotherapy with 90Y-ibritumomab tiuxetan or 131I-tositumomab. [2010.12]
I-131 tositumomab. [2010.08]
131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling. [2010.07]
Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study. [2010.06.20]
Methodology to incorporate biologically effective dose and equivalent uniform dose in patient-specific 3-dimensional dosimetry for non-Hodgkin lymphoma patients targeted with 131I-tositumomab therapy. [2010.04]
131I-Tositumomab (Bexxar) vs. 90Y-Ibritumomab (Zevalin) therapy of low-grade refractory/relapsed non-Hodgkin lymphoma. [2010.04]
Radioimmunotherapy of lymphoma: Bexxar and Zevalin. [2010.03]
Radiation therapy with tositumomab (B1) anti-CD20 monoclonal antibody initiates extracellular signal-regulated kinase/mitogen-activated protein kinase-dependent cell death that overcomes resistance to apoptosis. [2008.08.01]
Myeloablative 131I-tositumomab radioimmunotherapy in treating non-Hodgkin's lymphoma: comparison of dosimetry based on whole-body retention and dose to critical organ receiving the highest dose. [2008.05]
Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice. [2007.11]
Comparison of medium- and high-energy collimators for 131I-tositumomab dosimetry. [2007.09]
Iodine 131 tositumomab in the treatment of non-Hodgkin's lymphoma. [2007.06]
Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab. [2007.05.28]
High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma. [2007.04.10]
Safe administration of iodine-131 tositumomab after repeated infusion-related reactions to rituximab. [2007.03]
Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement. [2007.02]
Collimator selection, acquisition speed, and visual assessment of 131I-tositumomab biodistribution in a phantom model. [2006.12]
Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. [2006.09.01]
Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma. [2006.06.19]
Essential role of nuclear medicine technology in tositumomab and 131I-tositumomab therapeutic regimen for non-Hodgkin's lymphoma. [2006.06]
Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma. [2006.02.01]
Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. [2005.11.01]
Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. [2005.08.20]
Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. [2005.06.15]
A review of tositumomab and I(131) tositumomab radioimmunotherapy for the treatment of follicular lymphoma. [2005.04]
131I-tositumomab therapy as initial treatment for follicular lymphoma. [2005.02.03]
Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. [2005.02.01]
Development of 131I-tositumomab. [2005.02]
Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. [2005.01.20]
Tositumomab and (131)I therapy in non-Hodgkin's lymphoma. [2005.01]
Comparison of radiation dose estimation for myeloablative radioimmunotherapy for relapsed or recurrent mantle cell lymphoma using (131)I tositumomab to that of other types of non-Hodgkin's lymphoma. [2004.12]
Tositumomab and iodine [131I] tositumomab in the management of follicular lymphoma. An oncologist's view. [2004.12]
Radioimmunotherapy with tositumomab and iodine-131 tositumomab for low-grade non-Hodgkin lymphoma: nursing implications. [2004.11.16]
High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes. [2004.06]
Other possibly related research studies
[Radioimmunotherapy of follicular lymphoma: a step towards cure?] [2007.09.01]
Radioimmunotherapy as a therapeutic option for Non-Hodgkin's lymphoma. [2007.07]
Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphoma. [2007.08]
Novel concepts in radioimmunotherapy for non-Hodgkin's lymphoma. [2007.02]
Radiolabeled peptides and proteins in cancer therapy. [2007]
Radioimmunotherapy for non-Hodgkin's lymphoma. [2006.11]
Radioimmunotherapeutic strategies in autologous hematopoietic stem-cell transplantation for malignant lymphoma. [2006]
Radioimmunotherapy for B-cell non-Hodgkin lymphoma. [2006]
Cure of incurable lymphoma. [2006]
Radioimmunotherapy in a radiation oncology environment: building a multi-specialty team. [2006]
Pretargeted radioimmunotherapy. [2006]
Radioimmunotherapy for non-Hodgkin's lymphoma: a review for radiation oncologists. [2006.11.01]
[New substances in the therapy of head and neck cancer] [2006.07]
Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy. [2006.07]
Adverse effects of the humanized antibodies used as cancer therapeutics. [2006.07]
[Radioimmunotherapy for non-Hodgkin lymphoma: historical development and current status] [2006.01]
Review of clinical radioimmunotherapy. [2006.03]
Monoclonal antibody therapy. [2006.05.01]
[Radioimmunotherapy in non-Hodgkin's lymphoma. With focus on anti-CD20 treatment] [2005.10.10]
New developments in immunotherapy for non-Hodgkin's lymphoma. [2005.09]
Innovations in antineoplastic therapy. [2005.03]
Radio-immunotherapy in low-grade non-Hodgkin's lymphoma. [2005.03]
Radiometals as payloads for radioimmunotherapy for lymphoma. [2004.10]
Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma. [2004.10]
Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphoma. [2004.08.01]
Radioimmunotherapy: a new treatment modality for B-cell non-Hodgkin's lymphoma. [2004.05]
Radioimmunotherapy for treatment of B-cell lymphomas and other hematologic malignancies. [2007.11]
Effect of antilymphoma antibody, 131I-Lym-1, on peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma. [2007.08]
Perspectives of molecular imaging and radioimmunotherapy in lymphoma. [2008.03]
Radioimmunotherapy-based conditioning regimens for stem cell transplantation. [2008.04]
A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy. [2009.04.23]
Regularized reconstruction in quantitative SPECT using CT side information from hybrid imaging. [2010.05.07]
Arterial wall dosimetry for non-Hodgkin lymphoma patients treated with radioimmunotherapy. [2010.03]
Hypothyroidism: a growing complication of cancer treatment. [2009.10]
Use of integrated SPECT/CT imaging for tumor dosimetry in I-131 radioimmunotherapy: a pilot patient study. [2009.08]
Radioimmunotherapy in follicular lymphoma. [2011.06]
Radioimmunotherapy in non-Hodgkin lymphoma: opinions of nuclear medicine physicians and radiation oncologists. [2011.05]
New antibody drug treatments for lymphoma. [2011.05]
Radioimmunotherapy in follicular lymphoma: some like it hot.... [2011.04]
Bio-effect model applied to 131I radioimmunotherapy of refractory non-Hodgkin's lymphoma. [2011.05]
Radioimmunotherapy of solid tumors: searching for the right target. [2011.01]
Current concepts and future directions in radioimmunotherapy. [2010.12.01]
Maintenance and consolidation strategies in non-Hodgkin's lymphoma: A review of the data. [2010.11]
Optimal application of antibodies in the treatment of follicular lymphoma: current standards and future strategies. [2009.11]
Maintenance and consolidation strategies in non-Hodgkin's lymphoma: A review of
the data. [2010]
|
